Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome

Dr. Tesha Monteith, a migraine treatment expert, teams up with researcher Richard B. Lipton to explore the effects of Ubrogepant on migraines. They dive into a recent study highlighting how Ubrogepant can dramatically enhance patient-reported outcomes during the migraine prodrome phase. With significant boosts in functioning and patient satisfaction compared to a placebo, this discussion sheds light on innovative approaches in migraine care.